We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM) (ECLAM)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01111929
First Posted: April 28, 2010
Last Update Posted: November 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Omar Mamdouh Shaaban, Assiut University
April 23, 2010
April 28, 2010
November 22, 2017
January 2009
May 2016   (Final data collection date for primary outcome measure)
Initiation of long term contraception with 6 month postpartum [ Time Frame: 6 month ]
Same as current
Complete list of historical versions of study NCT01111929 on ClinicalTrials.gov Archive Site
  • Use/non-use of EC pills [ Time Frame: 6 months ]
  • Use/non-use of any other type of EC ( e.g insert IUD if eligible) [ Time Frame: 6 months ]
  • Pregnancy rate in each group [ Time Frame: 6 months ]
  • Side effects of LNG EC pills [ Time Frame: 6 months ]
  • The prevalence of unwanted pregnancy in each study group [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM)
Emergency Contraception as a Back up of Lactational Amenorrhea Method of Contraception

Prolonged breast-feeding is an encouraged tradition in Egypt. Breastfeeding is associated with variable degrees of amenorrhea and infertility but there is a risk of resumption of fertility and therefore, of conception during lactation. A consensus statement formalized the lactational amenorrhea method of contraception (LAM), which has subsequently been included in the family planning programs in some developing countries. It has proved to be effective with cumulative pregnancy rates ranging from only 0.9% to 1.2%. However, if any of the prerequisites of LAM expire at any time, the contraceptive efficacy will be much reduced.

The expiry of LAM requirements can occur unexpectedly at a time the woman is not ready to visit a clinic to initiate another contraceptive. Pregnancy during breast-feeding may result in mistimed, unplanned and sometimes unwanted childbirth. A study done in Egypt has shown that one in 4 of pregnancies during lactation were unplanned Such pregnancies, in addition to their negative social impact may lead some women to seek induced abortion; a procedure which, in settings (like Egypt) where abortion is illegal (except on very restricted grounds), is often unsafe.

Levonorgestrel 1.5 mg EC pills has been used for long time and proved to decrease the incidence of pregnancy by 75-85% in each act of unprotected sexual intercourse. Its safety has been documented. It can be used safely during lactation and has been classified by the WHO medical eligibility criteria for contraception as category-1 for lactating mother. Even if take early in pregnancy it is not abortifacient and does not by any mean affect the continuation of pregnancy or cause any side effects to the growing baby (WHO category 1).

The present study tries to estimate the efficacy of in advance provision of 1.5 Levonorgestrel EC pills (as a back-up of LAM) at the time of counseling of LAM when used in increasing the incidence of initiation of another long term method of contraception and probably decreasing the incidence of unintended pregnancy during breast-feeding in rural Egypt.

The investigators are planning to include all women who deliver in the investigators service and intent to breast-feed and planning of birth spacing. Women who refused to participate or planned to use a method of contraception other than LAM and those with expected difficulty of subsequent communication were excluded from participation.

All eligible participants will receive proper counseling for LAM by trained research nurse.

Women who choose to use LAM will be advised to return to the investigators contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires. All eligible participants who accept to participate in the study will be randomly assigned to one of two groups:Group 1 will only receive the above described care (control group). Group II (Intervention group) in which women will have the above proper counseling. Additionally, they will be advised to use the EC pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another contraceptive. Each women assigned to the intervention group will be supplied with one packet containing two 0.75 mg Levonorgestrel emergency contraceptive (EC) pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse. They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advise. All the above information will be additionally given to the patient in a small flyer.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Pregnancy During Breastfeeding
  • Lactational Amenorrhea Method
Drug: Counseling for LAM+ LNG-EC

They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.

They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.

  • Active Comparator: Counseling for LAM

    Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.

    Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires.

    Intervention: Drug: Counseling for LAM+ LNG-EC
  • Experimental: Counseling for LAM+ LNG-EC
    LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
    Intervention: Drug: Counseling for LAM+ LNG-EC

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1174
November 2016
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All women who delivers in the obstetric intent to breast-feed.
  • Eligible participants should have been planning of birth spacing

Exclusion Criteria:

  • Women refusal to participate in the study
  • Women planned to use a method of contraception other than LAM
  • Anticipation of difficulty of subsequent communication with the woman
Sexes Eligible for Study: Female
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01111929
ECLAM
Yes
Not Provided
Not Provided
Omar Mamdouh Shaaban, Assiut University
Assiut University
Not Provided
Principal Investigator: Omar M Shaaban, MD Department of Obstetrics and Gynecology, Assiut University, Egypt
Assiut University
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP